PMS eSTAR Draft Guidance Suggestions
Two stakeholders are proposing changes to an FDA draft guidance on the electronic submission template (eSTAR) for PMAs. In its comment letter, Abbott says it supports FDA’s goal of improving submission consistency and review efficiency through eSTAR. It focuses its comments on how the template and the accompanying procedures in the draft guidance can apply the PMA regulatory requirements predictably and in proportion to each submission type.
It makes these points:
- technical screening should stay administrative and should not reset review clocks;
- requirements for supplements and 30-day notices should match regulatory requirements;
- justified “not applicable” responses and cross-referencing should satisfy completeness; and
- implementation should be phased by submission type and protect submissions in progress.
In its response, AdvaMed says the draft guidance is “an important step towards a more modern and streamlined review process for PMA submissions. We agree that eSTAR offers many benefits, and we believe our suggestions will help refine the template and guidance to better suit submitted needs, particularly considering the agency’s proposal to require use of eSTAR to submit a PMA submission in the future.”
The association’s general comments are:
- preserve content flexibility currently afforded under eCopy format;
- implement transparency best practices that align with FDA priorities;
- ensure eSTAR guidance documents include sufficient information to understand the technical standards of the electronic submission template; and
- allow waivers and exemptions under appropriate circumstances.
Both Abbott and AdvaMed also submitted specific line-by-line comments.